Literature DB >> 32471573

Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.

Chao Zhang1, Li-Xu Yan2, Ben-Yuan Jiang1, Yi-Long Wu1, Wen-Zhao Zhong3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32471573     DOI： 10.1016/j.jtho.2019.12.133

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  7 in total

1.  Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer.

Authors:  Yan Hu; Siying Ren; Ruoyao Wang; Wei Han; Peng Xiao; Li Wang; Fenglei Yu; Wenliang Liu
Journal:  Front Pharmacol       Date:  2022-07-06       Impact factor: 5.988

2.  Feasibility and Safety of Neoadjuvant Alectinib in Pulmonary Invasive Mucinous Adenocarcinoma with ALK Rearrangement: Case Report and Literature Review.

Authors:  Rumeng Gu; Ziling Shi; Ting Duan; Meijun Song
Journal:  Onco Targets Ther       Date:  2021-10-21       Impact factor: 4.147

3.  Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.

Authors:  Shikang Zhao; Shuai Zhu; Xi Lei; Dongbo Xu; Tao Shi; Qiusong Chen; Fan Ren; Gang Chen; Dingzhi Huang; Song Xu
Journal:  Thorac Cancer       Date:  2021-08-17       Impact factor: 3.500

4.  Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement.

Authors:  Ning Zhou; Tong Li; Maoli Liang; Fan Ren; Hong Ni; Wei Liu; Tao Shi; Dongbo Xu; Qiusong Chen; Haonan Yu; Zuoqing Song; Lingling Zu; Shuo Li; Song Xu
Journal:  Front Oncol       Date:  2022-02-10       Impact factor: 6.244

5.  Neoadjuvant ceritinib treatment in ALK-rearranged locally advanced adenosquamous carcinoma: A case report.

Authors:  Shixiong Mai; Yue Wang; Xuemei Wang; Wei Yang; Haicheng Gao; Zhenan Xu; Lei Xu; Li Xu; Qiuxiang Ou; Hanlin Chen; Zhenxing Wang
Journal:  Thorac Cancer       Date:  2022-07-12       Impact factor: 3.223

Review 6.  Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer.

Authors:  Juejun Gong; Li Zhang
Journal:  Curr Opin Oncol       Date:  2021-01       Impact factor: 3.915

7.  Perioperative alectinib in a patient with locally advanced anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC): a case report.

Authors:  Ping Yue; Shengxiong Zhang; Ling Zhou; Jie Xiang; Shengguang Zhao; Xiaoyan Chen; Lei Dong; Wenjie Yang; Yi Xiang
Journal:  Transl Cancer Res       Date:  2021-08       Impact factor: 1.241
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.